Items Tagged ‘Pamrevlumab’

March 5, 2018

Pamrevlumab Awarded “Fast Track” Development Status for Treatment of Patients with Locally Advanced Pancreatic Cancer

By

CancerConnect News: The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the anti-CTGF antibody, pamrevlumab, for the treatment of patients with locally advanced unresectable pancreatic cancer. This follows review of the Phase 2 clinical trial evaluating pamrevlumab in combination with gemcitabine and nab-paclitaxel and represents recognition by the FDA that pamrevlumab […]

View full entry

Tags: locally advanced, News, Pamrevlumab, Pancreatic Cancer, Precision Cancer Medicine, treatment